LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in Enterococcus faecium
Recommended Citation
Axell-House DB, Simar SR, Panesso D, Rincon S, Miller WR, Khan A, Pemberton OA, Valdez L, Nguyen AH, Hood KS, Rydell K, DeTranaltes AM, Jones MN, Atterstrom R, Reyes J, Sahasrabhojane PV, Suleyman G, Zervos M, Shelburne SA, Singh KV, Shamoo Y, Hanson BM, Tran TT, and Arias CA. LiaX is a surrogate marker for cell envelope stress and daptomycin non-susceptibility in Enterococcus faecium. Antimicrob Agents Chemother 2024; 68(3):0106923.
Document Type
Article
Publication Date
3-6-2024
Publication Title
Antimicrobial agents and chemotherapy
Abstract
Daptomycin (DAP) is often used as a first-line therapy to treat vancomycin-resistant Enterococcus faecium infections, but emergence of DAP non-susceptibility threatens the effectiveness of this antibiotic. Moreover, current methods to determine DAP minimum inhibitory concentrations (MICs) have poor reproducibility and accuracy. In enterococci, DAP resistance is mediated by the LiaFSR cell membrane stress response system, and deletion of liaR encoding the response regulator results in hypersusceptibility to DAP and antimicrobial peptides. The main genes regulated by LiaR are a cluster of three genes, designated liaXYZ. In Enterococcus faecalis, LiaX is surface-exposed with a C-terminus that functions as a negative regulator of cell membrane remodeling and an N-terminal domain that is released to the extracellular medium where it binds DAP. Thus, in E. faecalis, LiaX functions as a sentinel molecule recognizing DAP and controlling the cell membrane response, but less is known about LiaX in E. faecium. Here, we found that liaX is essential in E. faecium with an activated LiaFSR system. Unlike E. faecalis, E. faecium LiaX is not detected in the extracellular milieu and does not appear to alter phospholipid architecture. We further postulated that LiaX could be used as a surrogate marker for cell envelope activation and non-susceptibility to DAP. For this purpose, we developed and optimized a LiaX enzyme-linked immunosorbent assay (ELISA). We then assessed 86 clinical E. faecium bloodstream isolates for DAP MICs and used whole genome sequencing to assess for substitutions in LiaX. All DAP-resistant clinical strains of E. faecium exhibited elevated LiaX levels. Strikingly, 73% of DAP-susceptible isolates by standard MIC determination also had elevated LiaX ELISAs compared to a well-characterized DAP-susceptible strain. Phylogenetic analyses of predicted amino acid substitutions showed 12 different variants of LiaX without a specific association with DAP MIC or LiaX ELISA values. Our findings also suggest that many E. faecium isolates that test DAP susceptible by standard MIC determination are likely to have an activated cell stress response that may predispose to DAP failure. As LiaX appears to be essential for the cell envelope response to DAP, its detection could prove useful to improve the accuracy of susceptibility testing by anticipating therapeutic failure.
Medical Subject Headings
Humans; Daptomycin; Enterococcus faecium; Phylogeny; Reproducibility of Results; Drug Resistance, Bacterial; Anti-Bacterial Agents; Cell Membrane; Biomarkers; Microbial Sensitivity Tests; Enterococcus faecalis; Gram-Positive Bacterial Infections
PubMed ID
38289081
ePublication
ePub ahead of print
Volume
68
Issue
3
First Page
0106923
Last Page
0106923
